PRGN 3005
Alternative Names: PRGN-3005; PRGN-3005 UltraCAR-TLatest Information Update: 08 Aug 2024
At a glance
- Originator Precigen Inc
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Suspended Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Most Recent Events
- 08 Aug 2024 Suspended - Phase-I for Fallopian tube cancer (Late-stage disease, Recurrent, Second-line therapy or greater) in USA (Intraperitoneal)
- 08 Aug 2024 Suspended - Phase-I for Fallopian tube cancer (Late-stage disease, Recurrent, Second-line therapy or greater) in USA (IV)
- 08 Aug 2024 Suspended - Phase-I for Ovarian cancer (Late-stage disease, Recurrent, Second-line therapy or greater) in USA (Intraperitoneal)